Finally, new animal models of familial and metastatic pheochromocytoma or paraganglioma will provide essential tools to test new approaches for diagnosis and treatment of tumors and the ...

Retifanlimab-dlwr (Zynyz) was granted approval from the FDA for treatment of locally recurrent or metastatic squamous cell ...

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma in patients over 12 years of age. The FDA has ...

Pheochromocytoma or Paraganglioma (PPGL) WELIREG is indicated for the treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic ...

for the treatment of adult and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). The approval was based on ...

for belzutifan for the treatment of adult and pediatric patients aged 12 years and older with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL). According to Merck ...

with priority review for treatment with Welireg (belzutifan), among adult and pediatric patients aged 12 years and older with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma ...

The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two rare types of adrenal gland tumors.

a person’s age, as pheochromocytoma tend to grow faster in people under 50 the size of the mass, with larger masses growing more quickly According to a 2022 study, masses less than 1 centimeter ...

for the treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). Pheochromocytoma and paraganglioma ...

unresectable or metastatic pheochromocytoma or paraganglioma (PPGL). This is the first FDA approval of an oral therapy for the treatment of patients with PPGL. Moreover, this regulatory approval was ...